Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Control Release ; 352: 623-636, 2022 12.
Article in English | MEDLINE | ID: mdl-36349615

ABSTRACT

Glioblastoma (GBM) is the most aggressive primary malignant brain tumor, with a median survival of approximately 15 months. Treatment is limited by the blood-brain barrier (BBB) which restricts the passage of most drugs to the brain. We previously reported the design and synthesis of a BBB-penetrant macrocyclic cell-penetrating peptide conjugate (M13) covalently linked at the axial position of a Pt(IV) cisplatin prodrug. Here we show the Pt(IV)-M13 conjugate releases active cisplatin upon intracellular reduction and effects potent in vitro GBM cell killing. Pt(IV)-M13 significantly increased platinum uptake in an in vitro BBB spheroid model and intravenous administration of Pt(IV)-M13 in GBM tumor-bearing mice led to higher platinum levels in brain tissue and intratumorally compared with cisplatin. Pt(IV)-M13 administration was tolerated in naïve nude mice at higher dosage regimes than cisplatin and significantly extended survival above controls in a murine GBM xenograft model (median survival 33 days for Pt(IV)-M13 vs 24 days for Pt(IV) prodrug, 22.5 days for cisplatin and 22 days for control). Increased numbers of γH2AX nuclear foci, biomarkers of DNA damage, were observed in tumors of Pt(IV)-M13-treated mice, consistent with elevated platinum levels. The present work provides the first demonstration that systemic injection of a Pt(IV) complex conjugated to a brain-penetrant macrocyclic peptide can lead to increased platinum levels in the brain and extend survival in mouse GBM models, supporting further development of this approach and the utility of brain-penetrating macrocyclic peptide conjugates for delivering non-BBB penetrant drugs to the central nervous system.


Subject(s)
Antineoplastic Agents , Glioblastoma , Prodrugs , Humans , Animals , Mice , Glioblastoma/drug therapy , Glioblastoma/pathology , Cisplatin , Prodrugs/therapeutic use , Platinum , Mice, Nude , Peptides/therapeutic use , Brain , Treatment Outcome , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/pharmacology , Cell Line, Tumor
2.
Bioorg Med Chem Lett ; 14(14): 3829-33, 2004 Jul 16.
Article in English | MEDLINE | ID: mdl-15203171

ABSTRACT

A series of bifunctional compounds was prepared consisting of 17beta estradiol linked to a DNA damaging N,N-bis-(2-chloroethyl)aniline. The objective of our studies was to determine the characteristics of the linker that permitted both reaction with DNA and binding of the resultant covalent adducts to the estrogen receptor. Linker characteristics were pivotal determinants underlying the ability of the compounds to kill selectively breast cancer cells that express the estrogen receptor.


Subject(s)
Aniline Compounds/therapeutic use , Antineoplastic Agents, Alkylating/chemical synthesis , Breast Neoplasms/drug therapy , Cell Survival/drug effects , Estradiol/therapeutic use , Aniline Compounds/chemistry , Aniline Compounds/pharmacology , Aniline Mustard , Antineoplastic Agents, Alkylating/pharmacology , Antineoplastic Agents, Alkylating/therapeutic use , Binding Sites , Breast Neoplasms/metabolism , DNA Adducts/metabolism , Dose-Response Relationship, Drug , Drug Design , Estradiol/chemistry , Estradiol/pharmacology , Evaluation Studies as Topic , Female , Humans , Receptors, Estrogen/metabolism , Tumor Cells, Cultured
3.
Neuron ; 31(5): 713-26, 2001 Sep 13.
Article in English | MEDLINE | ID: mdl-11567612

ABSTRACT

We have developed a presenilin-1 (PS1) conditional knockout mouse (cKO), in which PS1 inactivation is restricted to the postnatal forebrain. The PS1 cKO mouse is viable and exhibits no gross abnormalities. The carboxy-terminal fragments of the amyloid precursor protein differentially accumulate in the cerebral cortex of cKO mice, while generation of beta-amyloid peptides is reduced. Expression of Notch downstream effector genes, Hes1, Hes5, and Dll1, is unaffected in the cKO cortex. Although basal synaptic transmission, long-term potentiation, and long-term depression at hippocampal area CA1 synapses are normal, the PS1 cKO mice exhibit subtle but significant deficits in long-term spatial memory. These results demonstrate that inactivation of PS1 function in the adult cerebral cortex leads to reduced Abeta generation and subtle cognitive deficits without affecting expression of Notch downstream genes.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Peptides/biosynthesis , Amyloid beta-Protein Precursor/metabolism , Membrane Proteins/deficiency , Mice, Knockout/growth & development , Neuronal Plasticity/genetics , Synaptic Transmission/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Axons/metabolism , Axons/ultrastructure , Cerebral Cortex/growth & development , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Disease Models, Animal , Gene Expression Regulation, Developmental/physiology , Genetic Vectors/physiology , Hippocampus/growth & development , Hippocampus/metabolism , Hippocampus/physiopathology , Maze Learning/physiology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Memory Disorders/genetics , Memory Disorders/metabolism , Memory Disorders/physiopathology , Mice , Mice, Knockout/genetics , Mice, Knockout/metabolism , Neural Pathways/growth & development , Neural Pathways/metabolism , Neural Pathways/physiopathology , Presenilin-1 , Receptors, Notch , Signal Transduction/genetics , Space Perception/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...